SYS ONLINE
SUPPLEMENT_SCHOLAR
evidence · mechanism · dose
Experimental/GnRH AnalogResearch peptide

Nafarelin

aka Synarel

Intranasal GnRH agonist used in endometriosis and central precocious puberty.

Educational explainer of a research peptide. Profiles in this section deliberately omit clinical-trial citations, dosing protocols, and purchase links. Not FDA-approved as a supplement; not a recommendation to use.

Overview

Nafarelin is a long-acting GnRH agonist delivered by nasal spray, used to suppress the HPG axis after an initial flare.

Source
  • Approved pharmaceutical
Forms
  • Intranasal spray

Mechanism of action

Continuous GnRH receptor stimulation downregulates pituitary gonadotropin release, suppressing gonadal steroid output.

Pathways
  • · GnRH receptor
  • · LH/FSH suppression
  • · Gonadal steroid suppression
Hormones
  • · GnRH
  • · LH
  • · FSH
  • · Estradiol
  • · Testosterone

How it acts on the body

Used continuously, GnRH agonists first flare LH and FSH, then desensitize and downregulate the pituitary, producing a medical 'menopause' (or andropause). This is therapeutic in estrogen- or androgen-driven conditions.

Nafarelin is used in endometriosis to suppress estrogen-driven lesion activity and in central precocious puberty to halt premature pubertal progression while preserving eventual final height.

Hormonal & endocrine impact

How this peptide is reported to shift specific hormones and signaling molecules. Directionality reflects research literature and preclinical models, not clinical prescribing data.

Projected hormonal trajectory
Illustrative curves derived from reported direction of effect. Not measured patient data.

Curves are schematic shapes (sigmoid for increases/decreases, damped oscillation for modulation/stabilization) anchored to a 100% baseline. They communicate direction and tempo of change reported in research literature — not absolute hormone concentrations.

LH and FSHDecreases
Downregulation after initial flare.
EstradiolDecreases
Profound suppression to postmenopausal range.
TestosteroneDecreases
Castrate range in males.

Effects on the body

Decreases
Estrogen-driven endometriotic activity
Decreases
Premature pubertal progression

Organ system effects

Endocrine

HPG-axis suppression.

Reproductive

Suspension of cyclic ovarian or testicular function.

Bones

Density loss with prolonged use without add-back.

Reported effects

Drawn from preclinical research, anecdote, and small-scale clinical observation. No evidence grades are assigned — most peptides on this page lack rigorous human trials.

  • Non-injectable HPG-axis suppression
  • Reversible on discontinuation

Potential side effects

Common
  • · Hot flashes
  • · Vaginal dryness
  • · Mood changes
Rare
  • · Decreased libido
  • · Headache
Serious
  • · Bone loss with prolonged use
  • · Initial flare worsening of underlying disease

Drug interactions

Hormonal contraceptives
Confounds intended hormonal suppression.
moderate

Pairing context

Often combined with
  • Add-back hormone therapy in long courses
    Limits bone and vasomotor effects.
Avoid combining with
  • Pregnancy
    Contraindicated.
Important. Research peptides described here are not FDA-approved supplements. Supplement Scholar does not endorse, recommend, or link to any source for purchase. Consult a qualified clinician before considering any peptide therapy.